Todas las investigaciones
Activo, no reclutandoFASE3INTERVENCIONISTA

A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)

This research study is looking into a new treatment called zilganersen for Alexander Disease (AxD). The main goal is to find out if this medicine is safe and if it can help improve or stop the worsening of motor skills – that's your ability to move your body – for people living with AxD. The study involves a large number of participants and compares zilganersen with a placebo, which looks like the real medicine but contains no active ingredients. Participants won't know if they're getting the medicine or the placebo at first. After this initial period, everyone will have the chance to receive zilganersen. The study is particularly interested in how the medicine affects different aspects of movement and functioning in daily life.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE3
Patrocinador
Ionis Pharmaceuticals, Inc.
Objetivo de inscripción
54
Inicio
01 Jun 2021
Estimación de finalización
01 Jul 2034

¿De qué trata este estudio?

This study is investigating a new medicine called zilganersen specifically for people who have Alexander Disease (AxD). Alexander Disease is a very rare condition that affects the brain and can cause problems with movement, balance, and other body functions. There isn't a cure for AxD yet, so researchers are always looking for new ways to help.

The main purpose of this study is to see if zilganersen is safe for people with AxD, and if it can help improve or at least stabilise their movement abilities. This means looking at things like walking, using your hands, and other physical activities that might be affected by the disease. Half of the participants will receive the new medicine, while others will receive a placebo – a dummy treatment that looks just like the real medicine but has no active ingredients. This helps researchers truly understand if the medicine is making a difference.

This is a long-term study, and for the first part, neither you nor your doctor will know if you are receiving the medicine or the placebo. After this initial period, all participants will be offered the opportunity to receive zilganersen. The study also includes an option for younger children with AxD to take part. The hope is that zilganersen could offer a new way to manage the symptoms of Alexander Disease and improve the quality of life for those affected.

Puntos clave

  • This study is testing a new medicine, zilganersen, for Alexander Disease.
  • It aims to see if the medicine is safe and can help improve or stabilise your movement.
  • You might receive the medicine or a placebo (dummy treatment) initially.
  • Participation involves regular visits, assessments, and tests like MRI scans and lumbar punctures.
  • The study is long-term, lasting several years, with options for continued treatment.
  • It's crucial to meet specific health and age requirements to be eligible.

¿Quién puede ser elegible?

To join this study, participants need to have a clear diagnosis of Alexander Disease, confirmed by brain scans and genetic tests showing a specific change in the GFAP gene. Participants can be between 2 and 65 years old. It's important that you and your family (if you're under 18) are able to attend all the necessary appointments, which will involve travel to the study centre.

However, there are certain reasons why someone might not be able to join. For example, if you have other serious health problems, unusual blood test results, or can't have an MRI scan, you might not be eligible. Also, if you've recently taken part in other drug studies (within the last month to a year, depending on the drug) or had certain brain surgeries, gene therapies, or a specific type of brain shunt, you wouldn't be able to participate. The study team will review your full medical history to make sure it's safe for you to take part.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Do you have a confirmed diagnosis of Alexander Disease based on brain scans and genetic tests?
  2. Are you between 2 and 65 years old?
  3. Are you able to attend all required appointments at the study centre?
  4. Have you not participated in other drug studies recently (check with your doctor)?
  5. Have you not had certain brain surgeries, gene therapies, or shunts?
  6. Are you generally in good health, without other serious medical conditions that would prevent participation?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part, you'll be one of about 73 people with Alexander Disease in this study. For the first 60 weeks (about 14 months), you'll either receive the study medicine, zilganersen, or a placebo (a dummy treatment). You won't know which one you're getting. After this, everyone will then receive zilganersen for a further 60 weeks, and potentially for an even longer period of up to 120 weeks in an extension part of the study. There will also be a 28-week follow-up period after you stop taking the medicine.

Taking part will involve regular visits to the study centre. These visits will include checks of your health, physical examinations, and possibly tests like brain scans (MRIs) and lumbar punctures (where a small sample of fluid is taken from your spine). These are done to see how the medicine is affecting your body and the disease. If you are under 18, a parent or guardian will need to be with you and involved in the study requirements.

Riesgos y beneficios potenciales

There is a chance that zilganersen could help improve or steady your movement abilities, or it might not have any effect. We don't yet know what specific benefits, if any, the medicine might offer. As with all medicines, there's a risk of side effects, which the study will carefully monitor. You will undergo various medical procedures, some of which carry their own small risks. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (13)

  • Lucile Packard Children's Hospital Stanford
    Código postal verificado
    Palo Alto, Estados Unidos
  • Children's Hospital of Atlanta
    Código postal verificado
    Atlanta, Estados Unidos
  • Hospital General de Massachusetts
    Código postal verificado
    Boston, Estados Unidos
  • Hospital Infantil de Filadelfia
    Código postal verificado
    Filadelfia, Estados Unidos
  • Murdoch Children's Research Institute
    Código postal verificado
    Parkville, Australia
  • McGill University Health Centre
    Código postal verificado
    Montreal, Canadá
  • Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center
    Código postal verificado
    Tel Aviv, Israel
  • Ospedale dei Bambini Vittore Buzzi
    Código postal verificado
    Milan, Italy
  • Ospedale Pediatrico Bambino Gesù
    Código postal verificado
    Roma, Italia
  • National Center of Neurology and Psychiatry
    Código postal verificado
    Tokyo, Japan
  • Amsterdam Universitair Medische Centra - Academisch Medisch Centrum
    Código postal verificado
    Ámsterdam, Países Bajos
  • Fundación del NHS de los Hospitales del University College de Londres
    Código postal verificado
    Londres, Reino Unido

Preguntas comunes

¿Qué es un placebo?

A placebo is a substance that looks just like the real study medicine but doesn't contain any active ingredients. It helps researchers compare how effective the new medicine is against not receiving the active treatment.

What does 'Phase 3' mean for a study?

Phase 3 is usually one of the final stages of testing a new medicine before it can be approved for wider use. It involves a larger number of patients and aims to confirm the medicine's effectiveness and safety over a longer period.

Will I have to travel for this study?

Yes, you will need to travel to a designated study centre for your appointments, tests, and to receive your medication.

What is a lumbar puncture?

A lumbar puncture is a medical procedure where a small needle is used to collect a sample of spinal fluid from your lower back. This fluid can tell doctors important information about your brain and spinal cord.

What happens if I'm under 18?

If you're under 18, a parent or guardian will need to provide permission for you to join the study and will be involved in managing your participation and appointments.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.